Cefepime/zidebactam

Cefepime/zidebactam
Combination of
CefepimeCephalosporin antibacterial
ZidebactamBeta-lactamase inhibitor and non-beta-lactam antibacterial
Clinical data
Trade namesZaynich
AHFS/Drugs.comzaynich
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
KEGG

Cefepime/zidebactam, sold under the brand name Zaynich, is a fixed-dose combination used for the treatment of complicated urinary tract infections.[1] It contains cefepime, a cephalosporin antibacterial; and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.[1]

It was approved for medical use in the United States in May 2026.[2]

Medical uses

Cefepime/zidebactam is indicated for the treatment of adults with complicated urinary tract infections including pyelonephritis caused by designated susceptible microorganisms.[1]

Society and culture

Cefepime/zidebactam was approved for medical use in the United States in May 2026.[2][3]

Names

Cefepime/zidebactam is sold under the brand name Zaynich.[2]

References

  1. ^ a b c d https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220787Orig1s000lbl.pdf
  2. ^ a b c "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 1 June 2026. Retrieved 5 June 2026.
  3. ^ "Wockhardt Receives U.S. FDA Approval for Zaynich (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis" (Press release). Wockhardt. 1 June 2026. Retrieved 5 June 2026 – via PR Newswire.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.